
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
Supplements and Featured Publications
almost 26 years ago
Rountable Discussion: Glycemic Control and Economic Issuesalmost 26 years ago
Participating Facultyalmost 26 years ago
Introductionalmost 26 years ago
The Increasing Prevalence of Diabetes and its Economic Burdenalmost 26 years ago
Managing Diabetes for Improved Health and Economic Outcomes





